Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Garfield Heights, Ohio Clinical Trials

A listing of Garfield Heights, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (33) clinical trials

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

The purpose of this study is to evaluate itacitinib in combination with corticosteroids for the treatment of Grades II to IV acute graft-versus-host disease (aGVHD) in steroid-naive pediatric participants.

Phase

6.32 miles

Learn More »

CCR5-modified CD4+ T Cells for HIV Infection

This is a randomized clinical trial comparing the effect of infusing expanded autologous CD4+ T cells with or without ex vivo modification of the CCR5 gene by zinc finger nucleases among HIV-infected patients with plasma HIV RNA levels <50 copies/mL for at least 48 weeks and CD4+ T cell counts ...

Phase

6.32 miles

Learn More »

Improving SCI Rehabilitation Interventions by Retraining the Brain

This is a phase I/II Multi-site Clinical Trial. In this phase I/II randomized controlled study, 18 cervical spinal patients with upper limb impairments will receive non-invasive brain stimulation tDCS (Transcranial Direct Current Stimulation) to the area in the brain controlling the weaker muscle of the weakest upper limb while receiving ...

Phase

6.32 miles

Learn More »

A Study of TAK-981 in Combination With Rituximab in Participants With Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL)

The drug being tested in this study is called TAK-981 in combination with rituximab. The study will determine the safety, tolerability and efficacy of TAK-981 in combination with rituximab in participants with r/r CD20+ NHL. The study will include a dose escalation phase (Phase 1b) and an open label study ...

Phase

6.32 miles

Learn More »

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

Despite improvements achieved with the use of CPIs, 50-80% of cancer patients do not respond to this therapy. There is growing evidence that combining CPIs with other forms of immunotherapy has the potential to improve the desired effects of both CPIs and immunotherapies. This study looks at the safety and ...

Phase

6.32 miles

Learn More »

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

OUTLINE: This is a multi-center study. INVESTIGATIONAL TREATMENT: Phase Ib Dose-Finding Cohort I Cisplatin-Eligible: Phase Ib is a 3+3 design for the cisplatin-eligible group only. Cisplatin-eligible subjects receive: gemcitabine 1000mg/m2 IV D1 and D8 every 21 days repeated for 4 cycles; cisplatin 70mg/m2 IV D1 and D8 every 21 days, ...

Phase

6.32 miles

Learn More »

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Treatment will consist of 4 main phases: Remission Induction, Consolidation, Reinduction, and Maintenance. High risk patients will receive a reintensification phase prior to transplant in first remission. REMISSION INDUCTION: Chemotherapy will be given in an attempt to induce the participant's leukemia into remission. Drugs given are intrathecal triple drug treatment ...

Phase

6.32 miles

Learn More »

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

PRIMARY OBJECTIVES: (Phase I) I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion. (Phase II) II. Determine the ...

Phase

6.32 miles

Learn More »

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers.

Phase

6.37 miles

Learn More »

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Primary Objective: Establishment of safety of V+RICE in order to identify the recommended Phase II dose (RPD2) Secondary Objectives: Determine the overall response rate (ORR) of V+RICE relative to historical controls of RICE alone in r/r DLBCL. Determine the proportion of patients who proceed to autologous stem cell transplantation after ...

Phase

6.37 miles

Learn More »